C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy

• Published in: Scientific reports 2024-06, Vol.14 (1), p.13765-12
• Main Authors: Richlitzki, Cedric, Wiesweg, Marcel, Metzenmacher, Martin, Guberina, Nika, Pöttgen, Christoph, Hautzel, Hubertus, Eberhardt, Wilfried E. E., Darwiche, Kaid, Theegarten, Dirk, Aigner, Clemens, Bölükbas, Servet, Schuler, Martin, Stuschke, Martin, Guberina, Maja
• Format: Article
• Language: English
• Subjects: 631/67; 631/67/1612/1350; 692/308; 692/308/409; 692/53; 692/53/2421; 692/53/2422; 692/53/2423; Adult; Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor - blood; C-reactive protein; C-reactive protein (CRP); C-Reactive Protein - analysis; C-Reactive Protein - metabolism; Cancer therapies; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung - therapy; Chemoradiotherapy; Definitive radiochemotherapy; ESPATUE trial; Female; Humanities and Social Sciences; Humans; Immunotherapy; Inflammation; Laboratory values; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - radiotherapy; Lung Neoplasms - therapy; Male; Medical prognosis; Middle Aged; multidisciplinary; Neoplasm Staging; Non-small cell lung carcinoma; Overall survival; Patients; Peripheral blood; Prognosis; Radiation therapy; Risk groups; Science; Science (multidisciplinary); Small cell lung carcinoma; Stage III non-small cell lung cancer (NSCLC)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-64302-2

To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiochemotherapy at a high-volume cancer center. Seven blood biomarkers from 160 patients treated with definitive radiochemotherapy for stage III NSCLC were analyzed throughout the course treatment. Parameters were preselected using univariable and multivariable proportional hazards analysis and were assessed for internal validity using leave-one-out cross validation. Cross validated classifiers including biomarkers in addition to important clinical parameters were compared with classifiers containing the clinical parameters alone. An increased C-reactive protein (CRP) value in the final week of radiotherapy was found as a prognostic factor for overall survival, both as a continuous (HR 1.099 (1.038–1.164), p